Notably, four subunits of the calcium voltage-gated channel (CACN), which has been reported as a novel target for medulloblastoma therapy (Phan et al., 2017; Huang et al., 2018), were predicted, including calcium voltage-gated channel subunit alpha1 A (CACNA1A), calcium voltage-gated channel subunit alpha1 D (CACNA1D), calcium voltage-gated channel auxiliary subunit alpha2delta 1 (CACNA2D1), and calcium voltage-gated channel auxiliary subunit gamma 3 (CACNG3). This evidence concerns the gene CACNA2D1 and medulloblastoma.